News
An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...
EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.
14h
Stocktwits on MSNBMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism AliveBMO Capital opined on Monday that recent reports indicating Robert F. Kennedy Jr.'s plan to remove all members of the U.S.
TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...
Explore more
Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...
The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...
3d
InvestorsHub on MSNPositive CHMP Opinion for Gilead’s Lenacapavir in HIV PreventionGilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results